Massive study explores SGLT2 Drugs' impact on kidney anemia
NCT ID NCT07063316
First seen Mar 06, 2026 · Last updated Apr 29, 2026 · Updated 5 times
Summary
This study examines whether SGLT2 inhibitors, a type of diabetes drug, can delay or prevent anemia in people with chronic kidney disease. Researchers will compare 15,000 patients who take these drugs with those who don't, tracking lab results, treatments, and costs over two years. The goal is to understand how these medications affect anemia management in real-world settings.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for CHRONIC KIDNEY DISEASE are added.
Genom att skicka in godkänner du våra Användarvillkor
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
Genom att skicka in godkänner du våra Användarvillkor
Locations
-
Nippon Boehringer Ingelheim Co ., Ltd.
Tokyo, 1416017, Japan
Conditions
Explore the condition pages connected to this study.